DiagnaMed Announces Stock Option Grants and Shares for Debt Settlement TORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a life sciences company focused on molecular hydrogen and AI...

DiagnaMed Expands with Drug and Clinical Research AI Platform Leveraging proprietary EEG data from previous and future research studies with BRAIN AGE® Brain Health AI Accelerating clinical trial development and discovering potential novel treatments for...

DiagnaMed Cancels Previously Announced Private Placement TORONTO, July 03, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI,...

DiagnaMed Announces Appointment of New Director TORONTO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), a digital health generative AI company, announced today that Ms. Emily Davis resigned...

DiagnaMed Holdings Announces Listing on the Canadian Securities Exchange Focusing on novel AI-based digital diagnostics and therapeutics solutions for brain health Developing BRAIN AGE™, an electroencephalogram-based (EEG) artificial intelligence solution to detect an...